
About Panacea Biotec Limited
Data last updated:
Panacea Biotec Limited is a public limited company based in Lalru, Punjab, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 02 February 1984 and has been in existence for over 42 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L33117PB1984PLC022350. Its GSTIN is 03AAACP5335J1ZM (Punjab). The company holds 25 GST registrations, of which 23 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 531349 and NSE: PANACEABIO.
The company has an authorised share capital of ₹122.34 Cr and a paid-up capital of ₹22.26 Cr. It was formerly known as Panacea Drugs Ltd and Panacea Drugs Pvt Ltd. It is led by directors including Sandeep Jain (Managing Director) and Rajesh Jain (Managing Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ambala – Chandigarh Highway, Lalru, Punjab, India – 140501.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹639.77 Cr, a growth of 14.4% compared to the previous year. For the same year it recorded a net loss of ₹24.44 Cr (net margin -3.8%) and EBITDA of -₹4.66 Cr (EBITDA margin -0.7%). The net worth stands at ₹843.5 Cr (up 0.2% YoY). Total assets are valued at ₹890.34 Cr (down 1% YoY).
The company has about 1,092 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries and 1 joint venture.
As per MCA filings, the company has open charges of ₹739.69 Cr and satisfied charges of ₹3,545.32 Cr on record. Court records list 23 cases involving the company, including 16 filed by the company and 7 filed against it; 4 cases are pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website panaceabiotec.com.
Company details
Name history
Panacea Biotec has undergone 2 name changes throughout its history. The company was previously known as Panacea Drugs Ltd, and Panacea Drugs Pvt Ltd. The current legal name is Panacea Biotec Limited.
| Company Name | Status |
|---|---|
| Panacea Biotec Limited | Current |
| Panacea Drugs Ltd | Previous |
| Panacea Drugs Pvt Ltd | Previous |
CIN history
Panacea Biotec has one previous CIN (Corporate Identification Number): U33117PB1984PLC022350. The current CIN is L33117PB1984PLC022350, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L33117PB1984PLC022350 | Current |
| U33117PB1984PLC022350 | Previous |
Contact details
Panacea Biotec Limited's registered office is in Lalru, Punjab. Its website is panaceabiotec.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressAmbala – Chandigarh Highway, Lalru, Punjab, India – 140501
- IndustryLife Sciences, Biotechnology
To see the full contact details of Panacea Biotec Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Panacea Biotec Limited
FY 2025-26 filings availablePanacea Biotec Limited reported revenue of ₹639.77 Cr (up 14.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 640 | 559 | 559 | 460 | 661 | 625 | 544 |
| Revenue growth | +14.4% | -0.0% | +21.6% | -30.4% | +5.8% | +14.8% | - |
| EBITDA | (4.66) | (25.92) | (20.07) | (97.96) | (13.19) | 75.18 | 9.53 |
| EBITDA margin | -0.7% | -4.6% | -3.6% | -21.3% | -2.0% | +12.0% | +1.8% |
| Profit before tax | (7.37) | (7.96) | 1.47 | 12.80 | 1,449 | (146) | (178) |
| Net profit | (24.44) | (42.65) | (33.97) | (94.64) | (197) | (148) | (160) |
| Net profit margin | -3.8% | -7.6% | -6.1% | -20.6% | -29.8% | -23.6% | -29.4% |
| EPS (₹) | (0.88) | (1.37) | (0.19) | (5.43) | 176.05 | (24.11) | (31.72) |
| Balance sheet | |||||||
| Total assets | 890 | 899 | 909 | 921 | 983 | 813 | 1,064 |
| Net worth | 844 | 842 | 848 | 849 | 877 | (229) | 199 |
| Total debt | 15.00 | 15.00 | 15.00 | 15.24 | 34.16 | 820 | 742 |
| Cash & bank | 64.37 | 107 | 139 | 226 | 583 | 136 | 89.75 |
| Net working capital | 154 | 206 | 136 | 219 | 169 | 146 | 357 |
| Cash flow | |||||||
| Cash from operations | 16.69 | (27.37) | (0.10) | (422) | (108) | 107 | (30.47) |
| Cash from investing | (40.46) | 64.98 | 10.23 | 430 | 1,283 | (47.79) | (34.52) |
| Cash from financing | (1.06) | (2.66) | (2.81) | (18.37) | (1,176) | (47.11) | 90.74 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 190 | 200 | 167 | 165 | 141 | 167 | 133 | 163 |
| Revenue growth (YoY) | +34.4% | +19.7% | +25.8% | +1.0% | -4.2% | +44.1% | - | - |
| Other income | 9.37 | 6.98 | 5.26 | 5.05 | 9.10 | 16.99 | 36.30 | 6.39 |
| EBITDA | 15.50 | 5.67 | 2.57 | 11.74 | (17.79) | (1.18) | (26.88) | 7.96 |
| EBITDA margin | +8.2% | +2.8% | +1.5% | +7.1% | -12.6% | -0.7% | -20.3% | +4.9% |
| Depreciation | 7.28 | 7.90 | 7.88 | 8.45 | 8.34 | 8.39 | 8.42 | 8.98 |
| Interest | 0.60 | 1.18 | 1.20 | 1.85 | 2.14 | 0.86 | 1.04 | 0.99 |
| Profit before tax | 16.99 | 3.57 | (1.25) | 6.49 | (19.17) | 6.56 | (0.04) | 4.38 |
| Tax | 5.08 | 1.37 | (0.25) | 2.60 | (5.16) | 2.60 | 1.95 | (0.06) |
| Net profit | 11.91 | 2.20 | (1.00) | 3.89 | (14.01) | 3.96 | (1.99) | 4.44 |
| EPS (₹) | 1.90 | 0.38 | 0.08 | 0.65 | (2.20) | 0.66 | (0.31) | 0.74 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 413 | 310 | 360 | 257 | 236 | 344 | 158 |
| Revenue growth | +33.4% | -13.8% | +39.9% | +9.2% | -31.5% | +117.3% | - |
| EBITDA | (17.84) | (6.92) | 14.15 | (62.62) | (72.69) | 0.46 | (135) |
| EBITDA margin | -4.3% | -2.2% | +3.9% | -24.4% | -30.9% | +0.1% | -85.2% |
| Profit before tax | (43.90) | (26.05) | 4.19 | (62.74) | (93.59) | (12.88) | (136) |
| Net profit | (29.93) | (15.28) | 3.48 | (92.83) | (93.60) | (17.70) | (122) |
| Net profit margin | -7.2% | -4.9% | +1.0% | -36.1% | -39.8% | -5.2% | -77.0% |
| EPS (₹) | (4.88) | (2.49) | 0.58 | (14.29) | (15.28) | (2.36) | (24.99) |
| Balance sheet | |||||||
| Total assets | 584 | 572 | 480 | 448 | 515 | 594 | 978 |
| Net worth | 294 | 321 | 335 | 331 | 415 | 508 | 893 |
| Total debt | 256 | 221 | 119 | 97.47 | 84.16 | 65.08 | 67.24 |
| Cash & bank | 8.12 | 62.17 | 11.96 | 43.25 | 42.69 | 88.96 | 60.61 |
| Net working capital | 18.46 | 41.57 | (65.64) | (51.66) | 2.13 | 96.03 | 454 |
| Cash flow | |||||||
| Cash from operations | (40.17) | 3.94 | 33.07 | (10.74) | (52.69) | 38.27 | (82.86) |
| Cash from investing | (18.46) | (60.60) | (46.80) | 2.41 | 39.54 | (37.32) | (16.58) |
| Cash from financing | 22.54 | 90.07 | 12.82 | 9.01 | 9.83 | (7.20) | 109 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 127 | 135 | 111 | 99.31 | 90.81 | 112 | 67.90 | 108 |
| Revenue growth (YoY) | +39.5% | +20.0% | +63.7% | -8.4% | +18.5% | +97.4% | - | - |
| Other income | 6.41 | 6.06 | 5.60 | 3.84 | 3.61 | 4.95 | 6.09 | 3.32 |
| Total expenses | 108 | 127 | 111 | 101 | 105 | 115 | 86.47 | 93.04 |
| EBITDA | 18.50 | 7.30 | 0.30 | (1.38) | (13.70) | (3.02) | (18.57) | 15.39 |
| EBITDA margin | +14.6% | +5.4% | +0.3% | -1.4% | -15.1% | -2.7% | -27.3% | +14.2% |
| Depreciation | 4.51 | 4.47 | 4.18 | 4.89 | 4.91 | 4.77 | 4.91 | 5.21 |
| Interest | 6.32 | 6.89 | 6.33 | 7.04 | 5.93 | 6.00 | 4.64 | 3.85 |
| Profit before tax | 14.08 | 2.00 | (4.61) | (9.47) | (20.93) | (8.84) | (22.03) | 9.65 |
| Tax | 3.33 | 0.61 | (4.43) | (2.11) | (5.29) | (2.14) | (9.64) | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 190 | 200 | 167 | 165 | 141 | 167 | 133 | 163 |
| Revenue growth (YoY) | +34.4% | +19.7% | +25.8% | +1.0% | -4.2% | +44.1% | - | - |
| Other income | 9.37 | 6.98 | 5.26 | 5.05 | 9.10 | 16.99 | 36.30 | 6.39 |
| EBITDA | 15.50 | 5.67 | 2.57 | 11.74 | (17.79) | (1.18) | (26.88) | 7.96 |
| EBITDA margin | +8.2% | +2.8% | +1.5% | +7.1% | -12.6% | -0.7% | -20.3% | +4.9% |
| Depreciation | 7.28 | 7.90 | 7.88 | 8.45 | 8.34 | 8.39 | 8.42 | 8.98 |
| Interest | 0.60 | 1.18 | 1.20 | 1.85 | 2.14 | 0.86 | 1.04 | 0.99 |
| Profit before tax | 16.99 | 3.57 | (1.25) | 6.49 | (19.17) | 6.56 | (0.04) | 4.38 |
| Tax | 5.08 | 1.37 | (0.25) | 2.60 | (5.16) | 2.60 | 1.95 | (0.06) |
| Net profit | 11.91 | 2.20 | (1.00) | 3.89 | (14.01) | 3.96 | (1.99) | 4.44 |
| EPS (₹) | 1.90 | 0.38 | 0.08 | 0.65 | (2.20) | 0.66 | (0.31) | 0.74 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 640 | 559 | 559 | 460 | 661 | 625 | 544 |
| Revenue growth | +14.4% | -0.0% | +21.6% | -30.4% | +5.8% | +14.8% | - |
| Other income | 36.40 | 56.65 | 61.83 | 154 | 1,687 | 10.05 | 30.02 |
| Total expenses | 644 | 585 | 579 | 558 | 674 | 550 | 535 |
| Employee cost | 0.00 | 173 | 150 | 126 | 183 | 156 | 142 |
| EBITDA | (4.66) | (25.92) | (20.07) | (97.96) | (13.19) | 75.18 | 9.53 |
| EBITDA margin | -0.7% | -4.6% | -3.6% | -21.3% | -2.0% | +12.0% | +1.8% |
| Depreciation | 33.06 | 34.81 | 36.71 | 39.12 | 43.78 | 45.59 | 43.22 |
| Interest | 6.05 | 3.88 | 3.58 | 4.44 | 181 | 185 | 174 |
| Profit before tax | (7.37) | (7.96) | 1.47 | 12.80 | 1,449 | (146) | (178) |
| Tax | (0.21) | 0.77 | 2.98 | 46.55 | 371 | 1.95 | 16.64 |
| Net profit | (24.44) | (42.65) | (33.97) | (94.64) | (197) | (148) | (160) |
| Net profit margin | -3.8% | -7.6% | -6.1% | -20.6% | -29.8% | -23.6% | -29.4% |
| EPS (₹) | (0.88) | (1.37) | (0.19) | (5.43) | 176.05 | (24.11) | (31.72) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.79 | 13.33 | 12.12 | 11.11 | 6.13 | 6.13 | 6.13 |
| Reserves & surplus | 807 | 807 | 814 | 816 | 849 | (256) | 139 |
| Shareholders' funds (net worth) | 844 | 842 | 848 | 849 | 877 | (229) | 199 |
| Minority interest | (5.96) | (4.17) | (3.82) | (3.49) | (2.98) | (3.00) | (3.04) |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.24 | 0.29 | 760 | 709 |
| Unsecured loans | 15.00 | 15.00 | 15.00 | 15.00 | 33.87 | 60.03 | 33.55 |
| Total debt | 15.00 | 15.00 | 15.00 | 15.24 | 34.16 | 820 | 742 |
| Total liabilities | 890 | 899 | 909 | 921 | 983 | 813 | 1,064 |
| Assets | |||||||
| Gross block | 1,387 | 1,346 | 1,327 | 1,331 | 1,317 | 1,262 | 1,275 |
| Net block | 576 | 567 | 582 | 600 | 622 | 609 | 657 |
| Capital work in progress | 144 | 128 | 102 | 42.32 | 17.26 | 34.42 | 24.01 |
| Investments | 10.10 | 3.22 | 40.43 | 13.49 | 5.07 | 0.07 | 5.58 |
| Inventories | 193 | 214 | 178 | 202 | 213 | 174 | 148 |
| Sundry debtors | 73.52 | 72.56 | 57.42 | 60.09 | 81.66 | 84.68 | 68.52 |
| Cash & bank balances | 64.37 | 107 | 139 | 226 | 583 | 136 | 89.75 |
| Loans & advances | 172 | 180 | 69.98 | 60.73 | 67.90 | 116 | 377 |
| Total current assets | 503 | 573 | 445 | 549 | 946 | 511 | 683 |
| Total current liabilities | 349 | 367 | 309 | 330 | 776 | 365 | 326 |
| Net working capital | 154 | 206 | 136 | 219 | 169 | 146 | 357 |
| Total assets | 890 | 899 | 909 | 921 | 983 | 813 | 1,064 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 82.13 | 47.17 | 39.85 | 50.35 | 52.08 | 40.22 | 14.47 |
| Net cash from operating activities | 16.69 | (27.37) | (0.10) | (422) | (108) | 107 | (30.47) |
| Net cash from investing activities | (40.46) | 64.98 | 10.23 | 430 | 1,283 | (47.79) | (34.52) |
| Net cash from financing activities | (1.06) | (2.66) | (2.81) | (18.37) | (1,176) | (47.11) | 90.74 |
| Net change in cash | (24.82) | 34.95 | 7.32 | (10.50) | (1.74) | 11.86 | 25.75 |
| Closing cash | 64.37 | 107 | 139 | 226 | 583 | 136 | 89.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.4% | -0.0% | +21.6% | -30.4% | +5.8% | +14.8% | - |
| EBITDA growth | +82.0% | -29.2% | +79.5% | -642.7% | -117.5% | +688.9% | - |
| PBT growth | +7.2% | - | -88.5% | -99.1% | +9998.0% | +18.0% | - |
| Net income growth | +42.7% | -25.6% | +64.1% | +52.0% | -33.4% | +7.6% | - |
| Revenue CAGR (3Y) | +11.6% | -5.4% | -3.6% | -5.4% | +13.1% | +1.8% | 0.0% |
| EBITDA CAGR (3Y) | -63.7% | +25.3% | - | - | -53.9% | -3.5% | -41.3% |
| Profitability & leverage | |||||||
| Net income margin | -1.1% | -1.6% | -0.3% | -7.3% | +163.1% | -23.6% | -35.7% |
| Return on capital employed | -2.3% | -4.3% | -3.3% | -9.5% | -5.1% | 0.0% | 0.0% |
| Return on net worth | -3.2% | -5.3% | -4.1% | -11.1% | -60.8% | 0.0% | 0.0% |
| Debt / equity | 0.02 | 0.02 | 0.02 | 0.03 | 1.32 | 0.00 | 2.53 |
| Long-term debt / equity | 0.02 | 0.02 | 0.02 | 0.03 | 1.23 | 0.00 | 2.19 |
| Interest cover | -16.03 | -6.39 | -6.31 | -3.24 | -317.43 | 626.36 | -516.41 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.47 | 0.42 | 0.42 | 0.35 | 0.51 | 0.49 | 0.41 |
| Inventory turnover | 3.15 | 2.86 | 2.94 | 2.22 | 3.42 | 3.88 | 4.75 |
| Debtors turnover | 8.76 | 8.60 | 9.52 | 6.49 | 7.95 | 8.16 | 6.92 |
| EPS (₹) | (0.88) | (1.37) | (0.19) | (5.43) | 176.05 | (24.11) | (31.72) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 132.76 | 132.76 | 133.94 | 134.20 | 139.59 | (40.87) | 23.67 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 127 | 135 | 111 | 99.31 | 90.81 | 112 | 67.90 | 108 |
| Revenue growth (YoY) | +39.5% | +20.0% | +63.7% | -8.4% | +18.5% | +97.4% | - | - |
| Other income | 6.41 | 6.06 | 5.60 | 3.84 | 3.61 | 4.95 | 6.09 | 3.32 |
| Total expenses | 108 | 127 | 111 | 101 | 105 | 115 | 86.47 | 93.04 |
| EBITDA | 18.50 | 7.30 | 0.30 | (1.38) | (13.70) | (3.02) | (18.57) | 15.39 |
| EBITDA margin | +14.6% | +5.4% | +0.3% | -1.4% | -15.1% | -2.7% | -27.3% | +14.2% |
| Depreciation | 4.51 | 4.47 | 4.18 | 4.89 | 4.91 | 4.77 | 4.91 | 5.21 |
| Interest | 6.32 | 6.89 | 6.33 | 7.04 | 5.93 | 6.00 | 4.64 | 3.85 |
| Profit before tax | 14.08 | 2.00 | (4.61) | (9.47) | (20.93) | (8.84) | (22.03) | 9.65 |
| Tax | 3.33 | 0.61 | (4.43) | (2.11) | (5.29) | (2.14) | (9.64) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 413 | 310 | 360 | 257 | 236 | 344 | 158 |
| Revenue growth | +33.4% | -13.8% | +39.9% | +9.2% | -31.5% | +117.3% | - |
| Other income | 18.00 | 16.62 | 24.91 | 34.44 | 12.57 | 20.75 | 30.88 |
| Total expenses | 431 | 317 | 345 | 320 | 308 | 343 | 293 |
| Employee cost | 100 | 97.02 | 86.53 | 71.03 | 72.50 | 59.47 | 46.64 |
| EBITDA | (17.84) | (6.92) | 14.15 | (62.62) | (72.69) | 0.46 | (135) |
| EBITDA margin | -4.3% | -2.2% | +3.9% | -24.4% | -30.9% | +0.1% | -85.2% |
| Depreciation | 18.75 | 20.29 | 21.09 | 24.50 | 26.43 | 26.57 | 26.91 |
| Interest | 25.31 | 15.46 | 13.78 | 10.06 | 7.04 | 7.52 | 5.27 |
| Profit before tax | (43.90) | (26.05) | 4.19 | (62.74) | (93.59) | (12.88) | (136) |
| Tax | (13.97) | (10.83) | 0.66 | 24.79 | 0.00 | 1.56 | 17.10 |
| Net profit | (29.93) | (15.28) | 3.48 | (92.83) | (93.60) | (17.70) | (122) |
| Net profit margin | -7.2% | -4.9% | +1.0% | -36.1% | -39.8% | -5.2% | -77.0% |
| EPS (₹) | (4.88) | (2.49) | 0.58 | (14.29) | (15.28) | (2.36) | (24.99) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.79 | 13.33 | 12.12 | 11.11 | 6.13 | 6.13 | 6.13 |
| Reserves & surplus | 257 | 286 | 301 | 298 | 387 | 480 | 833 |
| Shareholders' funds (net worth) | 294 | 321 | 335 | 331 | 415 | 508 | 893 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.24 | 0.29 | 5.05 | 12.44 |
| Unsecured loans | 256 | 221 | 119 | 97.23 | 83.87 | 60.03 | 54.80 |
| Total debt | 256 | 221 | 119 | 97.47 | 84.16 | 65.08 | 67.24 |
| Total liabilities | 584 | 572 | 480 | 448 | 515 | 594 | 978 |
| Assets | |||||||
| Gross block | 883 | 863 | 901 | 909 | 908 | 893 | 905 |
| Net block | 417 | 416 | 423 | 435 | 454 | 464 | 499 |
| Capital work in progress | 131 | 119 | 96.54 | 27.85 | 0.88 | 12.97 | 3.74 |
| Investments | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 2.55 |
| Inventories | 126 | 152 | 108 | 116 | 129 | 87.04 | 99.23 |
| Sundry debtors | 30.68 | 20.85 | 11.08 | 12.27 | 23.32 | 35.29 | 17.69 |
| Cash & bank balances | 8.12 | 62.17 | 11.96 | 43.25 | 42.69 | 88.96 | 60.61 |
| Loans & advances | 119 | 89.92 | 52.53 | 27.52 | 53.57 | 81.26 | 437 |
| Total current assets | 284 | 325 | 184 | 199 | 249 | 293 | 614 |
| Total current liabilities | 266 | 283 | 249 | 251 | 247 | 197 | 161 |
| Net working capital | 18.46 | 41.57 | (65.64) | (51.66) | 2.13 | 96.03 | 454 |
| Total assets | 584 | 572 | 480 | 448 | 515 | 594 | 978 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 38.50 | 5.09 | 6.01 | 5.33 | 8.66 | 14.92 | 4.96 |
| Net cash from operating activities | (40.17) | 3.94 | 33.07 | (10.74) | (52.69) | 38.27 | (82.86) |
| Net cash from investing activities | (18.46) | (60.60) | (46.80) | 2.41 | 39.54 | (37.32) | (16.58) |
| Net cash from financing activities | 22.54 | 90.07 | 12.82 | 9.01 | 9.83 | (7.20) | 109 |
| Net change in cash | (36.09) | 33.41 | (0.91) | 0.67 | (3.32) | (6.26) | 9.96 |
| Closing cash | 8.12 | 62.17 | 11.96 | 43.25 | 42.69 | 88.96 | 60.61 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +33.4% | -13.8% | +39.9% | +9.2% | -31.5% | +117.3% | - |
| EBITDA growth | -157.8% | -148.9% | +122.6% | +13.9% | - | +100.3% | - |
| PBT growth | -68.5% | - | +9998.0% | +33.0% | -626.6% | +90.5% | - |
| Net income growth | -95.9% | -539.1% | +103.8% | +0.8% | -428.8% | +85.5% | - |
| Revenue CAGR (3Y) | +17.2% | +9.6% | +1.5% | +17.6% | +34.8% | +23.2% | -33.2% |
| EBITDA CAGR (3Y) | -34.2% | -54.3% | +213.3% | -22.5% | -20.9% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -7.2% | -4.9% | +1.0% | -34.1% | -39.7% | -4.2% | -96.8% |
| Return on capital employed | 0.0% | 0.0% | +3.3% | 0.0% | 0.0% | -1.1% | -8.2% |
| Return on net worth | 0.0% | 0.0% | +0.9% | 0.0% | 0.0% | -2.5% | -18.6% |
| Debt / equity | 0.78 | 0.52 | 0.32 | 0.24 | 0.16 | 0.09 | 0.58 |
| Long-term debt / equity | 0.64 | 0.41 | 0.32 | 0.24 | 0.16 | 0.09 | 0.42 |
| Interest cover | -69.17 | -56.82 | -198.56 | -11.55 | -7.10 | -28.80 | -3.26 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.47 | 0.35 | 0.40 | 0.28 | 0.26 | 0.38 | 0.18 |
| Inventory turnover | 2.97 | 2.38 | 3.21 | 2.10 | 2.18 | 3.69 | 2.23 |
| Debtors turnover | 16.05 | 19.41 | 30.80 | 14.45 | 8.04 | 12.97 | 7.37 |
| EPS (₹) | (4.88) | (2.49) | 0.58 | (14.29) | (15.28) | (2.36) | (24.99) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 43.03 | 47.72 | 50.20 | 49.63 | 64.24 | 79.43 | 136.97 |
To see the full year-wise statements and ratios of Panacea Biotec Limited, buy the company report.
Board of directors of Panacea Biotec Limited
Panacea Biotec has 9 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ankesh Jain Also directs: Panacea Biotec Pharma Limited, Adveta Power Private Limited | Whole-Time Director | 01 Apr 2016 | 10 Years 7 Months | Current |
| Sandeep Jain | Managing Director | 15 Nov 1984 | 42 Years 0 Months | Current |
| Rajesh Jain | Managing Director | 25 Nov 2006 | 19 Years 11 Months | Current |
| Krishan Kumar Jalan | Director | 14 Feb 2025 | 1 Years 9 Months | Current |
| Harshet Jain Also directs: MD Next Life Sciences LLP | Whole-Time Director | 14 Feb 2025 | 1 Years 9 Months | Current |
| Venkatesh Sarvasiddhi Also directs: Indiaspark (OPC) Private Limited | Director | 14 Feb 2025 | 1 Years 9 Months | Current |
Auditor
Panacea Biotec Limited is audited by Walker Chandiok & Co LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2024 | 001076N/N500013 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 72.50%, foreign institutional investors hold 2.30%, domestic institutional investors hold 2.30% and retail and other public shareholders hold 23.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 72.50% | 72.50% | 72.50% | 72.50% |
| Public | 27.50% | 27.50% | 27.50% | 27.50% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 06 Apr 2019 | 100261017 | Others | ₹739.69 Cr | Open | |
| 05 Jan 2022 | 100566669 | Axis Bank Limited | ₹29.61 Lakh | Satisfied | |
| 04 Feb 2020 | 100322594 | Others | ₹754.44 Cr | Satisfied | |
| 14 Nov 2017 | 100136189 | Others | ₹5.29 Cr | Satisfied | |
| 27 Dec 2014 | 10545518 | Sbicap Trustee Company Limited | ₹934.27 Cr | Satisfied |
To see the full charge records of Panacea Biotec Limited, buy the company report.
Total charge records: 39 View all charges
Legal cases
Panacea Biotec Limited has 23 court cases on record: 16 filed by Panacea Biotec, 7 filed against it. 4 cases are pending and 19 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 18 | 5 | 4 |
| High courts | 5 | 2 | 0 |
Cases on record (5 of 23)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South East, Delhi | Criminal case | Filed by the company against Green Life Infrastructure Development Corporation Ltd | Pending |
| High Court, CHANDIGARH (UT) | Company petition | Filed against the company by Praj Hipurity Systems Ltd | Disposed |
| High Court, PUNJAB | Company petition | Filed against the company by GMP Technical Solutions Pvt Ltd | Disposed |
| District court, South West, Delhi | Civil suit | Filed against the company by State | Pending |
| District court, New Delhi, Delhi | Court case (TRAFFIC CHALLAN) | Filed against the company by State | Pending |
To see the full case history of Panacea Biotec Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Panacea Biotec Limited was last rated by Care on 08 Feb 2019.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 08 Feb 2019 |
To see the full credit ratings and regulatory alerts of Panacea Biotec Limited, buy the company report.
MSME payment delays
Panacea Biotec Limited has 46 MSME Form 1 returns on record between 2009 and 2024, listing 2,403 overdue payments to 221 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 221)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| United Bio Fuel Industries | |||
| Oasis Tours India Private Limited | |||
| Scigenics (India) Private Limited | |||
| Url Aseptic Automation Inc. |
To see the full MSME payment records of Panacea Biotec Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Panacea Biotec has 2 subsidiary companies, 1 joint venture, and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Panacea Biotec Pharma Limited | U24299DL2019PLC347566 | |
| Meyten Realtech Private Limited | U70109PB2019PTC049328 |
To see the full group structure of Panacea Biotec Limited, buy the company report.
Employees & EPFO
Panacea Biotec Limited has a workforce of 1,092 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 1,092 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 | |
| FY 2015-16 | |
| FY 2014-15 |
To see the full employee and EPFO history of Panacea Biotec Limited, buy the company report.
GST
Panacea Biotec has 25 GST registrations: 23 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 03AAACP5335J1ZM | Punjab | Active | 01 Jul 2017 |
| 02AAACP5335J2ZN | Himachal Pradesh | Active | 01 Jul 2017 |
| 04AAACP5335J1ZK | Chandigarh | Active | 01 Jul 2017 |
| 05AAACP5335J1ZI | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Panacea Biotec Limited, buy the company report.
Recent activity
Panacea Biotec Limited has 53 board changes on record since 1984: 33 appointments and 20 cessations. The latest: Narotam Kumar Juneja ceased to be Director on 31 Mar 2025.
143 earlier events are in the company report.
News
From our blog
- Top Biotechnology Companies in India11 Aug 2020
Frequently asked questions
Panacea Biotec is an active public limited company based in Lalru, Punjab, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 02 February 1984 (42+ years old) and is registered under CIN L33117PB1984PLC022350. Listed on BSE: 531349 and NSE: PANACEABIO.
Panacea Biotec reported revenue of ₹639.77 Cr for FY 2025-26 (up 14.4% YoY) based on consolidated financials.
Panacea Biotec has 9 current directors:
- Sandeep Jain - Managing Director
- Rajesh Jain - Managing Director
- Ankesh Jain - Whole-Time Director
- Harshet Jain - Whole-Time Director
- Sanjay Trehan - Whole-Time Director
- Krishan Kumar Jalan - Director
- Venkatesh Sarvasiddhi - Director
- Rajender Pal Singh - Director
- Ambika Sharma - Director
The latest financial statements of Panacea Biotec on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Panacea Biotec is 03AAACP5335J1ZM, registered in Punjab. The company has 25 GST registrations in all, of which 23 are active and 2 are cancelled or inactive. Other active GSTINs include 02AAACP5335J2ZN (Himachal Pradesh), 04AAACP5335J1ZK (Chandigarh), 05AAACP5335J1ZI (Uttarakhand).
The CIN (Corporate Identification Number) of Panacea Biotec is L33117PB1984PLC022350. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Panacea Biotec is a listed company as per MCA records. Its shares are listed on both BSE (code: 531349) and NSE (symbol: PANACEABIO).
Panacea Biotec has 23 court cases on record: 16 filed by the company and 7 filed against it. 4 are pending. Most are in the district courts.
Panacea Biotec was incorporated on 02 February 1984, making it 42+ years old. It is registered with the Registrar of Companies, Chandigarh.
Narotam Kumar Juneja ceased to be Director on 31 Mar 2025. Manjula Upadhyay ceased to be Director on 29 Mar 2025. Harshet Jain was appointed as Whole-Time Director on 14 Feb 2025. Panacea Biotec has 53 board changes on record in total.
Panacea Biotec has 46 MSME Form 1 returns on record between 2009 and 2024, listing 2,403 overdue payments to 221 micro and small suppliers. The latest return was filed on 30 Apr 2024.

